ACCUEIL N°1 EN - NE PAS SUPPRIMER !
-
The Carnot Network will present at Viva Technology 2024 !
All about event
22 deeptech startups from the Carnot Network will present their technological offers on the Carnot booth (n°J01) at VivaTech !Did you know ? The Carnot Network propels more than 100 startups per year ! A great example of what public research can produce in terms of impact startups!
-
Viva Technology : ALTRANS ENERGIES, a startup from Carnot LSI presents its solution to strengthen the electricity grids of tomorrow
More informationALTRANS ENERGIES pioneers advanced solutions in global and predictive monitoring seamlessly integrating innovative sensing and quantum-inspired AI algorithms to enhance the resilience of grids and to reduce their maintenance cost.
⇒ Meet Cornel Ioana on 22 May at Carnot network booth n°J01
-
Viva Technology : CellEmax, a biotech startup from Carnot Inria, presents its unique AI-powered single-cell pharmacology approach to fight cancer
A future startup biotech, CellEmax specialized in the fast indentification of novel therapeutic targets for advanced Oncology. His Al-powered discovery platform identifies novel proteins to help re-sensitize cancer cells to immune system.
⇒ Meet Marielle Péré and Dr Jérémie Roux on 22 May at Carnot network booth n°J01
-
Viva Technology : Cereus Biosciences, startup from Carnot Curie Cancer, offers the universal, single cancer vaccine
Cereus Biosciences has developed a unique computational platform to explore the entire genome and identify mutations that encode tumor-specific neoantigens shared by patients.
⇒ Meet Jean-Pascal Tranie and Daniel Gautheret on 22 May at Carnot network booth n°J01
R&D partnership for innovation
News
The Carnot provide advanced technologies to more than 100 Deeptech start-ups per year.
Catherine Plessy succeeds Hubert Chameaud as Deputy Director General of the Association of Carnot Institutes (AiCarnot). She was previously responsible for the partnership development of the Carnot Icéel.
Partners since 2019, Institut Curie and Biomunex announce a new stage in their strategic research collaboration. Already co-inventor and 50% co-owner of this approach, Biomunex has signed an exclusive licensing agreement with Institut Curie for the clinical development of a new class of antibodies, capable of specifically targeting, engaging and redirecting MAIT cells to destroy cancer cells. A further step towards new, safer and more effective cutting-edge immunotherapies for the benefit of patients.
Under the effects of climate change, weather events are becoming more frequent and intense in terms of loss experience and damage costs. Lightweight structures such as houses and houses and roads, built on very plastic clay soils and sensitive to the shrinkage and swelling phenomena, suffer more degradations due to drought.
The Cerema, Institut Carnot Institute Clim'adapt, works and mobilizes those concerned to develop new remedial solutions to reduce the vulnerability of buildings exposed to the RGA and its resilience to climate change.
Neuroscientists and neurosurgeons from EPFL/CHUV/UNIL and CEA/FDD Clinatec/CHUGA/UGA report in the journal Nature that they have re-established the communication between the brain and spinal cord with a wireless digital bridge, allowing a paralyzed person to walk again naturally.
AVATAR MEDICAL helps surgeons better prepare their procedures through the use of virtual reality (VR) representations of their patients. These patient avatars are generated instantly from CT scan or MRI images with an underlying proprietary technology based on four years of research in human-data interaction and machine learning conducted at Institut Curie and Institut Pasteur (both Carnot Institute)
